EXTRACELLULAR GLYCATION crosslinks: prospects for removal Attenuation of EXTRACELLULAR MATRIX accumulation in diabetic nephropathy by the advanced GLYCATION end product cross-link BREAKER ALT-711 via a protein kinase C-α … Advanced GLYCATION endproduct CROSSLINKING in the cardiovascular system Advanced GLYCATION End Product Cross‐Linking: Pathophysiologic Role and Therapeutic Target in Cardiovascular Disease GLYCATION end-product cross-link BREAKER reduces collagen and improves cardiac function in AGING diabetic heart Advanced GLYCATION end-product cross-link BREAKERs: a novel approach to cardiovascular pathologies related to the AGING process Advanced GLYCATION endproduct crosslink BREAKER (alagebrium) improves endothelial function in patients with isolated systolic hypertension BREAKERs of advanced GLYCATION end products restore large artery properties in experimental diabetes Role of the AGE crosslink BREAKER, alagebrium, as a renoprotective agent in diabetes Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy A BREAKER of advanced GLYCATION end products attenuates diabetes-induced myocardial structural changes Crosslink BREAKERs: a new approach to cardiovascular therapy Advanced GLYCATION endproducts and osteoarthritis Accumulation of advanced GLYCATION endproducts reduces chondrocyte-mediated EXTRACELLULAR MATRIX turnover in human articular cartilage Cross-link BREAKERs as a new therapeutic approach to cardiovascular disease Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of AGING and diabetes The role of advanced GLYCATION end products in retinal ageing and disease AGE-BREAKERs cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats The AGE of the MATRIX: chemistry, consequence and cure Advanced GLYCATION: an important pathological event in diabetic and age related ocular disease The relationship between myocardial EXTRACELLULAR MATRIX remodeling and ventricular function Importance of advanced GLYCATION end products in diabetes-associated cardiovascular and renal disease Repairing EXTRACELLULAR AGING and GLYCATION Novel inhibitors of advanced GLYCATION endproducts Does accumulation of advanced GLYCATION end products contribute to the AGING phenotype? The role of AGEs in AGING: causation or correlation Diabetes and advanced GLYCATION endproducts Role of advanced GLYCATION end products in diabetic nephropathy Advanced GLYCATION end‐products (AGEs) and heart failure: pathophysiology and clinical implications AGEing and osteoarthritis: a different perspective Combination therapy with the advanced GLYCATION end product cross-link BREAKER, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or … Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link The breakdown of pre‐existing advanced GLYCATION end products is associated with reduced renal fibrosis in experimental diabetes EXTRACELLULAR MATRIX maturation in the left ventricle of normal and diabetic swine Inhibitors of the Maillard reaction and AGE BREAKERs as therapeutics for multiple diseases Advanced GLYCATION end-products: implications for diabetic and non-diabetic nephropathies The role of advanced GLYCATION end products in progression and complications of diabetes AGE, RAGE, and ROS in diabetic nephropathy Advanced GLYCATION endproducts (AGEs): pharmacological inhibition in diabetes Prevention and Repair of Protein Damage by the Maillard Reaction In Vivo Alagebrium chloride, a novel advanced GLYCATION end-product cross linkage BREAKER, inhibits neointimal proliferation in a diabetic rat carotid balloon injury … Advanced GLYCATION end products: a Nephrologist's perspective Collagen cross-link BREAKERs: a beginning of a new era in the treatment of cardiovascular changes associated with AGING,
GLYCATION and diabetic complications Role of GLYCATION in aging Mechanisms of GLYCATION in atherogenesis The pathological implications of protein GLYCATION. GLYCATION products and the pathogenesis of diabetic complications Free radical generation by early GLYCATION products: a mechanism for accelerated atherogenesis in diabetes Advanced GLYCATION end-products and atherosclerosis Inhibition of protein GLYCATION and advanced GLYCATION end products by ascorbic acid and other vitamins and nutrients Advanced GLYCATION endproducts in ageing and Alzheimer's disease GLYCATION and oxidation: a role in the pathogenesis of atherosclerosis Recent progress in advanced GLYCATION end products and diabetic complications Protein GLYCATION and oxidative stress in diabetes mellitus and ageing Tobacco smoke is a source of toxic reactive GLYCATION products Hydrogen peroxide production during experimental protein GLYCATION Diabetes, advanced GLYCATION endproducts and vascular disease Atherogenesis and Advanced GLYCATION: Promotion, Progression, and Preventiona Advanced GLYCATION end products in Alzheimer's disease and other neurodegenerative diseases Recent progress in advanced GLYCATION and diabetic vascular disease: role of advanced GLYCATION end product receptors Lipoprotein GLYCATION and its metabolic consequences Advanced GLYCATION end products, oxidant stress and vascular lesions GLYCATION of collagen: the basis of its central role in the late complications of ageing and diabetes Formation of crossline as a fluorescent advanced GLYCATION end productin vitroandin vivo Advanced GLYCATION end products contribute to amyloidosis in Alzheimer disease GLYCATION of proteins as a source of superoxide. Advanced GLYCATION end products increase retinal vascular endothelial growth factor expression. Renal catabolism of advanced GLYCATION end products: the fate of pentosidine Survey of the distribution of a newly characterized receptor for advanced GLYCATION end products in tissues Plasma levels of pentosidine in diabetic patients: an advanced GLYCATION end product. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced GLYCATION endproducts Advanced GLYCATION endproducts and cigarette smoking. Cytotoxicity of advanced GLYCATION endproducts is mediated by oxidative stress GLYCATION induces expansion of the molecular packing of collagen In vitro kinetic studies of formation of antigenic advanced GLYCATION end products (AGEs): novel inhibition of post-Amadori GLYCATION pathways Lipoprotein GLYCATION and its metabolic consequences. Enhanced cellular oxidant stress by the interaction of advanced GLYCATION end products with their receptors/binding proteins Determination of advanced GLYCATION end products in serum by fluorescence spectroscopy and competitive ELISA Effect of phosphate on the kinetics and specificity of GLYCATION of protein. Pathways of formation of glycoxidation products during GLYCATION of collagen Breakers of advanced GLYCATION end products restore large artery properties in experimental diabetes Implication of an increased oxidative stress in the formation of advanced GLYCATION end products in patients with end-stage renal failure Non-enzymic GLYCATION of individual plasma proteins in normoglycemic and hyperglycemic patients. Role of fructose in GLYCATION and cross-linking of proteins The Advanced GLYCATION End Product, N∊-(Carboxymethyl) lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (∗) Advanced GLYCATION end products up-regulate gene expression found in diabetic glomerular disease Vascular hypertrophy in experimental diabetes. Role of advanced GLYCATION end products. Orally absorbed reactive GLYCATION products (glycotoxins): an environmental risk factor in diabetic nephropathy The role of GLYCATION cross-links
The HPA axis is involved in the neurobiology of mood disorders and functional illnesses, including anxiety disorder, bipolar disorder, insomnia, posttraumatic stress disorder, borderline personality disorder, ADHD, major depressive disorder, burnout, chronic fatigue syndrome, fibromyalgia, irritable bowel syndrome, and alcoholism.[15] Antidepressants, which are routinely prescribed for many of these illnesses, serve to regulate HPA axis function.[16] Sex differences are prevalent in humans with respect to psychiatric stress-related disorders such as anxiety and depression, where women experience these disorders more often than men.[17] Particularly in rodents, it has been shown that females may lack the ability to tolerate as well as process stress (particularly for chronic stress) due to possible down regulation of GR expression as well as a deficiency of FKBP51 binding protein in the cytosol. By constantly activating the HPA axis, this could lead to higher instances of stress and disorders that would only get worse with chronic stress.[18] Specifically in rodents, females show greater activation of the HPA axis following stress than males. These differences also likely arise due to the opposing actions that certain sex steroids have, such as testosterone and oestrogen. Oestrogen functions to enhance stress-activated ACTH and CORT secretion while testosterone functions to decrease HPA axis activation and works to inhibit both ACTH and CORT responses to stress.[19] However, more studies are required to better understand the underlying basis of these sex differences. Experimental studies have investigated many different types of stress, and their effects on the HPA axis in many different circumstances.[20] Stressors can be of many different types—in experimental studies in rats, a distinction is often made between "social stress" and "physical stress", but both types activate the HPA axis, though via different pathways.[21] Several monoamineneurotransmitters are important in regulating the HPA axis, especially dopamine, serotoninand norepinephrine (noradrenaline). There is evidence that an increase in oxytocin, resulting for instance from positive social interactions, acts to suppress the HPA axis and thereby counteracts stress, promoting positive health effects such as wound healing.[22] The HPA axis is a feature of mammals and other vertebrates. For example, biologists studying stress in fish showed that social subordination leads to chronic stress, related to reduced aggressive interactions, to lack of control, and to the constant threat imposed by dominant fish. Serotonin (5HT) appeared to be the active neurotransmitter involved in mediating stress responses, and increases in serotonin are related to increased plasma α-MSH levels, which causes skin darkening (a social signal in salmonoid fish), activation of the HPA axis, and inhibition of aggression. Inclusion of the amino acid L-tryptophan, a precursor of 5HT, in the feed of rainbow troutmade the trout less aggressive and less responsive to stress.[23] However, the study mentions that plasma cortisol was not affected by dietary L-tryptophan. The drug LY354740(also known as Eglumegad, an agonist of the metabotropic glutamate receptors 2 and 3) has been shown to interfere in the HPA axis, with chronic oral administration of this drug leading to markedly reduced baseline cortisol levels in bonnet macaques (Macaca radiata); acute infusion of
Free γ -AMINOBUTYRIC ACID in brain The action of γ -AMINOBUTYRIC ACID on cortical neurones γ -AMINOBUTYRIC ACID in brain: its formation from glutamic ACID Biochemical-physiology correlations in studies of the γ -AMINOBUTYRIC ACID system Factor I and γ -AMINOBUTYRIC ACID Epilepsy and γ -AMINOBUTYRIC ACID -mediated inhibition The Nature of γ -AMINOBUTYRIC ACID γ -AMINOBUTYRIC -ACID deficiency in brain of schizophrenic patients Cortical inhibition and γ -AMINOBUTYRIC ACID Glutamate and γ -AMINOBUTYRIC ACID in brain Some metabolic studies of γ -AMINOBUTYRIC ACID . γ -AMINOBUTYRIC ACID in peripheral tissues Hepatic encephalopathy and the γ -AMINOBUTYRIC -ACID neurotransmitter system γ -AMINOBUTYRIC ACID and cardiovascular function Behavioral evidence for the involvement of γ -AMINOBUTYRIC ACID in the actions of ethanol Huntington's chorea: Deficiency of γ -AMINOBUTYRIC ACID in brain Blood-brain barrier to H3-γ -AMINOBUTYRIC ACID in normal and amino oxyacetic ACID -treated animals Aspartate, glutamate and γ -AMINOBUTYRIC ACID depolarize cultured astrocytes Orally active and potent inhibitors of γ -AMINOBUTYRIC ACID uptake THE EFFECT OF HYPOXIA ON BRAIN γ ‐AMINOBUTYRIC ACID LEVELS1 Effects of acute and chronic pentobarbitone on the γ -AMINOBUTYRIC ACID system in rat brain Immunohistochemical identification of γ -AMINOBUTYRIC ACID -containing neurons in the rat basolateral amygdala The γ -AMINOBUTYRIC ACID -α-ketoglutaric ACID transaminase of beef brain Metabolic and neurophysiological roles of γ -AMINOBUTYRIC ACID Betel nut constituents as inhibitors of γ -AMINOBUTYRIC ACID uptake Levels of γ -AMINOBUTYRIC ACID in cerebrospinal fluid in various neurologic disorders Cerebrospinal fluid γ -AMINOBUTYRIC ACID variations in neurological disorders Decreased CSF concentrations of homovanillic ACID and γ -AMINOBUTYRIC ACID in Alzheimer's disease: age-or disease-related modifications? Regional distribution of γ ‐AMINOBUTYRIC ACID (GABA ) in brain of the rhesus monkey Stress‐induced alterations in metabolism of γ ‐AMINOBUTYRIC ACID in rat brain Role of γ -AMINOBUTYRIC ACID (GABA ) in the extrapyramidal motor system γ -AMINOBUTYRIC ACID -glutamic ACID transamination in brain γ -AMINOBUTYRIC ACID , a neurotransmitter, induces planktonic abalone larvae to settle and begin metamorphosis Role of γ -AMINOBUTYRIC ACID in anxiety Rapid accumulation of γ -AMINOBUTYRIC ACID and alanine in soybean leaves in response to an abrupt transfer to lower temperature, darkness, or mechanical … The occurrence of γ -AMINOBUTYRIC ACID in human tissues other than brain Properties of γ -AMINOBUTYRIC ACID (GABA ) receptor binding in rat brain synaptic membrane fractions Studies on the GABA pathway—I: The inhibition of γ -AMINOBUTYRIC ACID -α-ketoglutaric ACID transaminase in vitro and in vivo by U-7524 (Amino-oxyacetic ACID ) Two types of γ ‐AMINOBUTYRIC ACID receptor on embryonic sensory neurones Measurement of γ ‐AMINOBUTYRIC ACID in isolated nerve cells of cat central nervous system The role of γ -AMINOBUTYRIC ACID in the mechanism of seizures Anaerobic Accumulation of γ -AMINOBUTYRIC ACID and Alanine in Radish Leaves (Raphanus sativus, L.) Low cerebrospinal fluid γ ‐AMINOBUTYRIC ACID content in seizure patients Binding of [3H] α-dihydropicrotoxinin, a γ -AMINOBUTYRIC ACID synaptic antagonist, to rat brain membranes DEPOLARIZING ACTIONS OF γ ‐AMINOBUTYRIC ACID AND RELATED COMPOUNDS ON RAT SUPERIOR CERVICAL GANGLIA IN VITRO The release of γ
DYNORPHIN 1–8 and DYNORPHIN 1–9 are ligands for the κ-subtype of opiate receptor Behavioral effects and in vivo degradation of intraventricularly administered DYNORPHIN-(1-13) and D-Ala2-DYNORPHIN-(1-11) in rats DYNORPHIN is a specific endogenous ligand of the kappa opioid receptor Specific receptor for the opioid peptide DYNORPHIN: structure--activity relationships DYNORPHIN-(1-13), an extraordinarily potent opioid peptide Enhancement of DYNORPHIN gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor … Dopamine differentially regulates DYNORPHIN, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/DYNORPHIN precursor Porcine pituitary DYNORPHIN: complete amino acid sequence of the biologically active heptadecapeptide Effect of low-and high-frequency TENS on Met-enkephalin-Arg-Phe and DYNORPHIN A immunoreactivity in human lumbar CSF DYNORPHIN and vasopressin: common localization in magnocellular neurons Altered patterns of DYNORPHIN immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy Distribution of DYNORPHIN and enkephalin peptides in the rat brain DYNORPHIN immunocytochemistry in the rat central nervous system Cocaine-induced c-fos messenger RNA is inversely related to DYNORPHIN expression in striatum Dopamine D1 receptor mutant mice are deficient in striatal expression of DYNORPHIN and in dopamine-mediated behavioral responses DYNORPHIN is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity Differential activation of spinal cord DYNORPHIN and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal DYNORPHIN biosynthesis in a rat model of peripheral inflammation and … The opioid peptide DYNORPHIN mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation Opioid receptor selectivity of DYNORPHIN gene products. Comparison of the distribution of DYNORPHIN systems and enkephalin systems in brain Nonopiate effects of DYNORPHIN and des-Tyr-DYNORPHIN Antinociception and paralysis induced by intrathecal DYNORPHIN A. Optimization of solid-phase synthesis of [Ala8]-DYNORPHIN A DYNORPHIN expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and DYNORPHIN in neurons of the dorsal root ganglia of … Intrathecal DYNORPHIN A1–13 and DYNORPHIN A3–13 reduce rat spinal cord blood flow by non-opioid mechanisms Vasopressin, oxytocin, DYNORPHIN, enkephalin and corticotrophin‐releasing factor mRNA stimulation in the rat. Predominance of the amino-terminal octapeptide fragment of DYNORPHIN in rat brain regions DYNORPHIN increases in the dorsal spinal cord in rats with a painful peripheral neuropathy Immunoreactive DYNORPHIN in pituitary and brain DYNORPHIN A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture Involvement of DYNORPHIN and the kappa opioid receptor in feeding DYNORPHIN opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters DYNORPHIN-immunoreactive neurons in the central nervous system of the rat DYNORPHIN‐related peptides cause motor dysfunction in the rat through a non‐opiate action Stimulation of hypothalamic β-endorphin and DYNORPHIN release by corticotropin-releasing factor (in vitro) Cocaine selectively increases striatonigral DYNORPHIN levels by a dopaminergic mechanism Regional distribution of DYNORPHIN and neo-endorphin peptides in rat brain, spinal cord, and pituitary
TRYPTOPHAN HYDROXYLASE -2 controls brain serotonin synthesis TRYPTOPHAN HYDROXYLASE 2 (TPH2 ) gene variants associated with ADHD TRYPTOPHAN HYDROXYLASE -2 (TPH2 ) in disorders of cognitive control and emotion regulation: a perspective Loss-of-function mutation in TRYPTOPHAN HYDROXYLASE -2 identified in unipolar major depression Amygdala responsiveness is modulated by TRYPTOPHAN HYDROXYLASE -2 gene variation TRYPTOPHAN HYDROXYLASE -2 gene variation influences personality traits and disorders related to emotional dysregulation Brain-specific TRYPTOPHAN HYDROXYLASE 2 (TPH2 ): a functional Pro2 06Ser substitution and variation in the 5′-region are associated with bipolar affective disorder A regulatory variant of the human TRYPTOPHAN HYDROXYLASE -2 gene biases amygdala reactivity Functional domains of human TRYPTOPHAN HYDROXYLASE 2 (hTPH2 ) Impaired executive control is associated with a variation in the promoter region of the TRYPTOPHAN HYDROXYLASE 2 gene Effect of TRYPTOPHAN HYDROXYLASE -2 gene variants on suicide risk in major depression TRYPTOPHAN HYDROXYLASE 2 (TPH2 ) haplotypes predict levels of TPH2 mRNA expression in human pons Elevated expression of TRYPTOPHAN HYDROXYLASE -2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides TRYPTOPHAN HYDROXYLASE 2 gene is associated with major depression and antidepressant treatment response Up-regulation of TRYPTOPHAN HYDROXYLASE -2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in TRYPTOPHAN HYDROXYLASE 2 (Tph2 ) loss-of-function mice Transmission disequilibrium of polymorphic variants in the TRYPTOPHAN HYDROXYLASE -2 gene in attention-deficit/hyperactivity disorder Genotype-dependent activity of TRYPTOPHAN HYDROXYLASE -2 determines the response to citalopram in a mouse model of depression Association of functional polymorphisms of the human TRYPTOPHAN HYDROXYLASE 2 gene with risk for bipolar disorder in Han Chinese In silico analysis of the TRYPTOPHAN HYDROXYLASE 2 (TPH2 ) protein variants related to psychiatric disorders Activation and stabilization of human TRYPTOPHAN HYDROXYLASE 2 by phosphorylation and 14-3-3 binding Haplotype-based linkage of TRYPTOPHAN HYDROXYLASE 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations Additive effects of serotonin transporter and TRYPTOPHAN HYDROXYLASE -2 gene variation on emotional processing Advances in TRYPTOPHAN HYDROXYLASE ‐2 gene expression regulation: New insights into serotonin–stress interaction and clinical implications TRYPTOPHAN HYDROXYLASE -2 : an emerging therapeutic target for stress disorders TRYPTOPHAN HYDROXYLASE 1 knockout and TRYPTOPHAN HYDROXYLASE 2 polymorphism: effects on hypoxic pulmonary hypertension in mice A TRYPTOPHAN HYDROXYLASE 2 gene polymorphism is associated with panic disorder Estrogen receptor beta regulates the expression of TRYPTOPHAN-HYDROXYLASE 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei No human TRYPTOPHAN HYDROXYLASE -2 gene R441H mutation in a large cohort of psychiatric patients and control subjects Effect of TRYPTOPHAN HYDROXYLASE -2 gene variants on amygdalar and hippocampal volumes TRYPTOPHAN-HYDROXYLASE 2 haplotype association with borderline personality disorder and aggression in a sample of patients with personality disorders and healthy … Transmission disequilibrium of polymorphic variants in the TRYPTOPHAN HYDROXYLASE -2 gene in children and adolescents with obsessive–compulsive disorder 1, 2 5‐Dihydroxyvitamin D regulates expression of the TRYPTOPHAN HYDROXYLASE 2 and leptin genes: implication for behavioral influences of vitamin
HYPOCRETIN (OREXIN ) deficiency in human narcolepsy HYPOCRETIN (OREXIN ) loss in Parkinson's disease Neurons containing HYPOCRETIN (OREXIN ) project to multiple neuronal systems Behavioral correlates of activity in identified HYPOCRETIN /OREXIN neurons HYPOCRETIN (OREXIN ) loss in Alzheimer's disease The HYPOCRETIN /OREXIN system HYPOCRETIN (OREXIN ) cell loss in Parkinson's disease Release of HYPOCRETIN (OREXIN ) during waking and sleep states HYPOCRETIN (OREXIN ): role in normal behavior and neuropathology The HYPOCRETIN /OREXIN ligand–receptor system: implications for sleep and sleep disorders HYPOCRETIN /OREXIN in arousal and stress A role for HYPOCRETIN (OREXIN ) in male sexual behavior Hypothalamic HYPOCRETIN (OREXIN ): robust innervation of the spinal cord A role for HYPOCRETIN /OREXIN in motivation The sleep disorder canine narcolepsy is caused by a mutation in the HYPOCRETIN (OREXIN ) receptor 2 gene The HYPOCRETIN /OREXIN system: an increasingly important role in neuropsychiatry Loss of HYPOCRETIN (OREXIN ) neurons with traumatic brain injury HYPOCRETIN /OREXIN excites HYPOCRETIN neurons via a local glutamate neuron—a potential mechanism for orchestrating the hypothalamic arousal system The HYPOCRETIN (OREXIN ) system: from a neural circuitry perspective Leptin receptor-and STAT3-immunoreactivities in HYPOCRETIN /OREXIN neurones of the lateral hypothalamus. CSF HYPOCRETIN /OREXIN levels in narcolepsy and other neurological conditions HYPOCRETIN /OREXIN contributes to the expression of some but not all forms of stress and arousal IGFBP3 colocalizes with and regulates HYPOCRETIN (OREXIN ) HYPOCRETIN /OREXIN overexpression induces an insomnia-like phenotype in zebrafish The HYPOCRETIN /OREXIN system in health and disease HYPOCRETIN (OREXIN ) regulation of sleep-to-wake transitions Low cerebrospinal fluid HYPOCRETIN (OREXIN ) and altered energy homeostasis in human narcolepsy HYPOCRETIN (OREXIN ) activation and synaptic innervation of the locus coeruleus noradrenergic system HYPOCRETIN (OREXIN ) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area Sleep, sleep disorders and HYPOCRETIN (OREXIN ) HYPOCRETIN /OREXIN , sleep and narcolepsy The wake-promoting HYPOCRETIN –OREXIN neurons are in an intrinsic state of membrane depolarization Wake-promoting and sleep-suppressing actions of HYPOCRETIN (OREXIN ): basal forebrain sites of action The HYPOCRETIN /OREXIN system mediates the extinction of fear memories Identification and functional analysis of mutations in the HYPOCRETIN (OREXIN ) genes of narcoleptic canines Regulation of HYPOCRETIN (OREXIN ) expression in embryonic zebrafish Localized loss of HYPOCRETIN (OREXIN ) cells in narcolepsy without cataplexy HYPOCRETIN /OREXIN disturbances in neurological disorders A commentary on the neurobiology of the HYPOCRETIN /OREXIN system Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, HYPOCRETIN /OREXIN The HYPOCRETIN –OREXIN system regulates cocaine self‐administration via actions on the mesolimbic dopamine system Narp immunostaining of human HYPOCRETIN (OREXIN ) neurons: loss in narcolepsy HYPOCRETIN (OREXIN ) biology and the pathophysiology of narcolepsy with cataplexy Predictors of HYPOCRETIN (OREXIN ) deficiency in narcolepsy without cataplexy Synaptic interaction between HYPOCRETIN (OREXIN ) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and … HYPOCRETIN (OREXIN ) neuromodulation of stress and reward pathways HYPOCRETIN /OREXIN depolarizes and decreases potassium conductance in locus coeruleus neurons
Harnessing NEUROPLASTICITY for clinical applications NEUROPLASTICITY in children Conceptualizing functional NEUROPLASTICITY Homer2 is necessary for EtOH-induced NEUROPLASTICITY Stress, depression, and NEUROPLASTICITY: a convergence of mechanisms Threoretical aspects of NEUROPLASTICITY Toward a theory of NEUROPLASTICITY Antidepressants and NEUROPLASTICITY Mitochondria and NEUROPLASTICITY Central NEUROPLASTICITY and pathological pain NEUROPLASTICITY subserving motor skill learning NEUROPLASTICITY mediated by altered gene expression The musician's brain as a model of NEUROPLASTICITY Learning in the fast lane: new insights into NEUROPLASTICITY Training-induced NEUROPLASTICITY in young children Invited Review: NEUROPLASTICITY in respiratory motor control Natural rewards, NEUROPLASTICITY, and non-drug addictions Contribution of central NEUROPLASTICITY to pathological pain: review of clinical and experimental evidence Evidence for four forms of NEUROPLASTICITY Mitochondria in NEUROPLASTICITY and neurological disorders Social influences on NEUROPLASTICITY: stress and interventions to promote well-being NEUROPLASTICITY: from MRI to depressive symptoms NEUROPLASTICITY and rehabilitation NEUROPLASTICITY and cellular resilience in mood disorders Drug addiction as a pathology of staged NEUROPLASTICITY Transcranial magnetic stimulation and NEUROPLASTICITY The dark side of NEUROPLASTICITY Buddha's brain: NEUROPLASTICITY and meditation [in the spotlight] The dynamic brain: NEUROPLASTICITY and mental health Alterations of NEUROPLASTICITY in depression: the hippocampus and beyond NEUROPLASTICITY in Alzheimer's disease NEUROPLASTICITY and swallowing NEUROPLASTICITY in the context of motor rehabilitation after stroke Principles of NEUROPLASTICITY and behavior Developmental NEUROPLASTICITY after cochlear implantation Corticosteroid receptors and NEUROPLASTICITY NEUROPLASTICITY and its applications for rehabilitation What blindness can tell us about seeing again: merging NEUROPLASTICITY and neuroprostheses NEUROPLASTICITY in mood disorders Dynamic network connectivity: a new form of NEUROPLASTICITY Structural and functional NEUROPLASTICITY in relation to traumatic stress Stress during development: Impact on NEUROPLASTICITY and relevance to psychopathology NEUROPLASTICITY failure in Alzheimer's disease: bridging the gap between plaques and tangles Exercise and NEUROPLASTICITY in persons living with Parkinson's disease NEUROPLASTICITY promoted by task complexity Studies of NEUROPLASTICITY with transcranial magnetic stimulation Functional and structural imaging of pain-induced NEUROPLASTICITY NEUROPLASTICITY, psychosocial genomics, and the biopsychosocial paradigm in the 21st century NEUROPLASTICITY and functional recovery in multiple sclerosis NEUROPLASTICITY of neocortical circuits in schizophrenia NEUROPLASTICITY and brain repair after stroke Modification of hippocampal neurogenesis and NEUROPLASTICITY by social environments Enteric NEUROPLASTICITY evoked by inflammation NEUROPLASTICITY—exercise-induced response of peripheral brain-derived neurotrophic factor D1-receptor impact on NEUROPLASTICITY in humans Harnessing NEUROPLASTICITY for clinical applications Brain damage and NEUROPLASTICITY: mechanisms of recovery or development? Neural interface technology for rehabilitation: exploiting and promoting NEUROPLASTICITY Sex differences in cortical NEUROPLASTICITY in humans NEUROPLASTICITY in the mesolimbic dopamine system and cocaine addiction Vulnerability to depression: from brain NEUROPLASTICITY to identification of biomarkers Preemptive analgesia. Clinical evidence of NEUROPLASTICITY contributing to postoperative pain. Dynamic NEUROPLASTICITY after human prefrontal cortex damage NEUROPLASTICITY and cognitive aging: the scaffolding theory of aging and cognition NEUROPLASTICITY and constraint-induced movement therapy Cellular mechanisms of NEUROPLASTICITY NEUROPLASTICITY signaling pathways linked to the pathophysiology of schizophrenia Systems NEUROPLASTICITY in the aging brain: recruiting additional neural resources for successful motor performance in elderly persons NEUROPLASTICITY following non-penetrating traumatic brain injury Stress risk factors and stress-related pathology: NEUROPLASTICITY, epigenetics and endophenotypes Impairments of NEUROPLASTICITY and cellular resilience in severe mood disorders: implications for
CATALASE The mechanism of CATALASE action. I. Steady-state analysis CATALASE activity Some variables affecting the measurement of “CATALASE activity” in soil A spectrophotometric method for measuring the breakdown of hydrogen peroxide by CATALASE Perborate as substrate in a new assay of CATALASE On the mechanism of the decomposition of hydrogen peroxide by CATALASE CATALASE photoinactivation The molecular weight of crystalline CATALASE Photometric determination of CATALASE activity The reaction between aminotriazole and CATALASE New method for CATALASE determination Hydrogen peroxide formation and CATALASE activity in the lactic acid bacteria CATALASE: kinetics of photooxidation Effect of temperature on CATALASE activity A study of the inhibition of CATALASE by 3-amino-1: 2: 4-triazole An intermediate compound in the CATALASE-hydrogen peroxide reaction Isoniazid-resistance and CATALASE activity of tubercle bacilli: a preliminary report The reactions of CATALASE in the presence of the notatin system The kinetics of CATALASE synthesis and destruction in vivo Reaction between CATALASE and hydrogen peroxide Crystalline bacterial CATALASE Effect of pH upon the reaction kinetics of the enzyme-substrate compounds of CATALASE Properties of CATALASE. Catalysis of coupled oxidation of alcohols CATALASE production by lactobacilli Purification of horse-radish peroxidase and comparison of its properties with those of CATALASE and methaemoglobin CATALASE. II The mechanism of CATALASE inhibitions CATALASE OF THE LACTOBACILLACEAE The effect of CATALASE on the inhibine and peroxide values of various honeys Production of CATALASE by the pediococci Activity of CATALASE in the red cell Dissociation of CATALASE into subunits Production of CATALASE changes in animals with 3-amino-1, 2, 4-triazole The enzyme-substrate compounds of bacterial CATALASE and peroxides On some properties of CATALASE haematin Liver CATALASE I. A manometric determination of CATALASE activity Denaturation of CATALASE by freezing and thawing The reactions of azide with CATALASE and their significance Studies on the CATALASE activity of acid-fast bacilli: I. An attempt to subgroup these organisms on the basis of their CATALASE activities at different temperatures and pH The state of CATALASE in the respiring bacterial cell Spectroscopy of CATALASE CATALASE assay with special reference to manometric methods On the detailed mechanism of a new type of CATALASE-like action The decomposition of hydrogen peroxide by liver CATALASE Dissociation of bovine liver CATALASE at low pH Further Studies of the Liver CATALASE A toxic cancer tissue constituent as evidenced by its effect on liver CATALASE activity Interrelationships of CATALASE, peroxidase, hematin, and chlorophyll Peroxidatic activity of CATALASE CATALASE studies on normal and cancerous rats The effect of pH upon the equilibria of CATALASE compounds Selectivity of sorbic acid media for the CATALASE negative lactic acid bacteria and clostridia CATALASE Studies on Isoniazid and Tubercle Bacilli, II. The Growth Requirements, CATALASE Activities, and Pathogenic Properties of Isoniazid-Resistant Mutants Studies on rat liver CATALASE II. Incorporation of 14C-leucine into CATALASE of liver cell fractions in vivo CATALASE, a new enzym of general occurrence An ultracentrifugal study of CATALASE Liver CATALASE Studies on rat liver CATALASE I. Combined immunochemical and enzymatic determination of CATALASE in liver cell fractions CATALASE, peroxidase and metmyoglobin as catalysts of coupled peroxidatic
Stress, CORTICOTROPIN -RELEASING FACTOR , and behavior Chemical and biological characterization of CORTICOTROPIN RELEASING FACTOR Psychiatric implications of basic and clinical studies with CORTICOTROPIN -RELEASING FACTOR CORTICOTROPIN -RELEASING FACTOR has an anxiogenic action in the social interaction test Effects of CORTICOTROPIN -RELEASING FACTOR and growth hormone-RELEASING FACTOR on sleep and activity in rats Influence of CORTICOTROPIN -RELEASING FACTOR on reproductive functions in the rat Behavioral effects of CORTICOTROPIN -RELEASING FACTOR : localization and characterization of central effects Isolation and sequence analysis of the human CORTICOTROPIN ‐RELEASING FACTOR precursor gene. CORTICOTROPIN -RELEASING FACTOR : actions on the sympathetic nervous system and metabolism Stress-induced inhibition of reproductive functions: role of endogenous CORTICOTROPIN -RELEASING FACTOR Characterization of rat hypothalamic CORTICOTROPIN -RELEASING FACTOR Primary structure of CORTICOTROPIN -RELEASING FACTOR from ovine hypothalamus CORTICOTROPIN RELEASING FACTOR decreases postburst hyperpolarizations and excites hippocampal neurons Interleukin-1 stimulates the secretion of hypothalamic CORTICOTROPIN -RELEASING FACTOR CORTICOTROPIN RELEASING FACTOR produces behavioural activation in rats CORTICOTROPIN -RELEASING FACTOR -producing neurons in the rat activated by interleukin-1 Elevated concentrations of CSF CORTICOTROPIN -RELEASING FACTOR -like immunoreactivity in depressed patients Intraventricular CORTICOTROPIN -RELEASING FACTOR enhances behavioral effects of novelty CORTICOTROPIN -RELEASING FACTOR receptors are widely distributed within the rat central nervous system: an autoradiographic study The role of CORTICOTROPIN -RELEASING FACTOR in the pathogenesis of major depression Immunocytochemical localization of CORTICOTROPIN ‐RELEASING FACTOR (CRF) in the rat brain In vivo CORTICOTROPIN -RELEASING FACTOR -induced secretion of adrenoCORTICOTROPIN , β-endorphin, and corticosterone Mediation by CORTICOTROPIN RELEASING FACTOR (CRF) of adenohypophysial hormone secretion [38] Assay of CORTICOTROPIN RELEASING FACTOR CORTICOTROPIN -RELEASING FACTOR immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study CORTICOTROPIN -RELEASING FACTOR : effects on the autonomic nervous system and visceral systems. Hypothalamic control of adrenoCORTICOTROPIN secretion: advances since the discovery of 41-residue CORTICOTROPIN -RELEASING FACTOR Mechanisms of action of CORTICOTROPIN -RELEASING FACTOR and other regulators of CORTICOTROPIN release in rat pituitary cells. CORTICOTROPIN -RELEASING FACTOR receptors in the rat central nervous system: characterization and regional distribution CSF CORTICOTROPIN -RELEASING FACTOR -like immunoreactivity in depression and schizophrenia. CORTICOTROPIN -RELEASING FACTOR directly mediates colonic responses to stress Catecholaminergic modulation of CORTICOTROPIN -RELEASING FACTOR and adrenoCORTICOTROPIN secretion Reduced CORTICOTROPIN RELEASING FACTOR binding sites in the frontal cortex of suicide victims Distribution of CORTICOTROPIN -RELEASING FACTOR in rat brain. Organization of ovine CORTICOTROPIN -RELEASING FACTOR immunoreactive cells and fibers in the rat brain: an immunohistochemical study Clinical applications of CORTICOTROPIN -RELEASING FACTOR Interaction of CORTICOTROPIN -RELEASING FACTOR and Arginine Vasopressin on AdrenoCORTICOTROPIN Secretion in Vivo Physiological and behavioral responses to CORTICOTROPIN -RELEASING FACTOR administration: is CRF a mediator of anxiety or stress responses? CORTICOTROPIN -RELEASING FACTOR : effects on the sympathetic nervous system and oxygen consumption Synthetic competitive antagonists of CORTICOTROPIN -RELEASING FACTOR : effect on ACTH secretion in the rat CORTICOTROPIN -RELEASING FACTOR as the mediator of stress responses The CORTICOTROPIN -RELEASING FACTOR stimulation test: an aid in the evaluation of patients with Cushing's syndrome CORTICOTROPIN -RELEASING FACTOR potentiates acoustic startle in rats: blockade by chlordiazepoxide Effects of